Related Experiment Video

Updated: Nov 16, 2025

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
05:14

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

511

CAR Ts and BiTEs Shine in Multiple Myeloma

    Cancer Discovery
    |February 23, 2021
    PubMed

    Insights

    Chimeric antigen receptor T-cell therapies and bispecific T-cell engagers show promise for relapsed or refractory multiple myeloma. Early trials indicate comparable efficacy, with neither treatment strategy currently outperforming the other.

    Area of Science:

    • Hematology
    • Immunotherapy
    • Oncology

    Background:

    • Relapsed or refractory multiple myeloma presents a significant clinical challenge.
    • Novel immunotherapies are being investigated to improve patient outcomes.

    Discussion:

    • Chimeric antigen receptor (CAR) T-cell therapies and bispecific T-cell engagers (BiTEs) represent emerging treatment modalities.
    • Both CAR T-cell and BiTE therapies target specific antigens on myeloma cells to elicit an immune response.

    Key Insights:

    • Early clinical trials suggest that both CAR T-cell treatments and BiTE therapies demonstrate efficacy in patients with relapsed or refractory multiple myeloma.
    • Current evidence indicates a similar level of effectiveness between these two distinct therapeutic strategies.

    Outlook:

    • Further research and larger clinical trials are necessary to definitively compare the long-term efficacy, safety, and optimal use of CAR T-cell and BiTE therapies.
    • Head-to-head comparisons will be crucial for determining the superior treatment approach in multiple myeloma management.

    More Related Videos

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

    Published on: February 16, 2015

    21.8K
    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

    Published on: February 17, 2022

    3.6K

    Related Concept Videos

    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
    856
    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
    9.1K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.1K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.5K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    5.6K